imaprelimab   Click here for help

GtoPdb Ligand ID: 9805

Synonyms: PRX-003 | PRX003
Immunopharmacology Ligand
Compound class: Antibody
Comment: Imaprelimab (PRX-003) is an anti-MCAM mAb developed as a novel therapy for psoriasis. In patients with autoimmune diseases, a subset of MCAM+ve T cells (which have an effector memory T-helper 17 phenotype) produce high levels of pro-inflammatory IL-17 [1,3]. Pharmacological disruption of MCAM function is thought to be a valid mechanism for the treatment of autoimmune inflammation. Peptide sequence alignments identify imaprelimab as one of the preferred antibodies claimed in patent WO2014039975 [2] (SEQ IDs 119 and 123 match the sequences submitted to the WHO for INN imaprelimab). These peptide sequences map to the construct identified as h2120VH5/L3.
Click here for help
References
1. Dagur PK, McCoy Jr JP. (2015)
Endothelial-binding, proinflammatory T cells identified by MCAM (CD146) expression: Characterization and role in human autoimmune diseases.
Autoimmun Rev, 14 (5): 415-22. [PMID:25595133]
2. Flanagan K, Baker J, Yednock TA. (2014)
Anti-mcam antibodies and associated methods of use.
Patent number: WO2014039975. Assignee: Neotope Biosciences Limited. Priority date: 10/09/2012. Publication date: 13/03/2012.
3. Wu C, Goodall JC, Busch R, Gaston JS. (2015)
Relationship of CD146 expression to secretion of interleukin (IL)-17, IL-22 and interferon-γ by CD4(+) T cells in patients with inflammatory arthritis.
Clin Exp Immunol, 179 (3): 378-91. [PMID:25113810]